Cargando…
PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
Targeting mutant BRAF in patients with melanomas harboring this oncogene has been highly successful as a first-line treatment, but other mutations may affect its efficacy and alter the route of acquired resistance resulting in recurrence and poor prognosis. As an evolving strategy, melanoma treatmen...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289936/ https://www.ncbi.nlm.nih.gov/pubmed/34282258 http://dx.doi.org/10.1038/s41698-021-00207-x |